New drug hopes to shield transplanted kidneys from protein damage
NCT ID NCT07356388
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether finerenone can reduce protein in the urine (proteinuria) of people who have had a kidney transplant. Proteinuria is a sign of kidney damage. The study compares finerenone plus standard care to dapagliflozin plus standard care in 54 adult patients. The main goal is to see if finerenone lowers urine protein levels and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Finerenone
- What this could lead to
- If it works, finerenone could offer a new way to reduce proteinuria and protect kidney function in transplant recipients, potentially delaying further kidney damage.
- What could go wrong
- This is a small, early-phase trial with only 54 participants. The drug may not outperform the standard treatment, and side effects like high potassium or kidney issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE AFTER KIDNEY TRANSPLANTATION WITH PROTEINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changhai Hospital
Shanghai, Shanghai Municipality, 200082, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.